ArQule, Inc. (NASDAQ:ARQL)

CAPS Rating: 2 out of 5

A clinical-stage biotechnology company, engaged in the research and development of cancer therapeutics. Its mission is to research, develop and commercialize targeted cancer drugs with reduced toxicities compared to conventional cancer chemotherapeutics.

Recs

0
Player Avatar zacprince (76.44) Submitted: 9/24/2007 8:41:15 PM : Outperform Start Price: $7.50 ARQL Score: -13.50

best wall street player likes it, there probably smarter than me, so im going for it.

Report this Post 1 Comment
Member Avatar kaskoosek (99.69) Submitted: 1/4/2009 7:54:36 AM
Recs: 0

wall street playerare you crazy.

Featured Broker Partners


Advertisement